US Needs to Think Global in Life Science R&D Practices
America is going to be the world’s largest economy for the next 20 years. And then it won’t be. To survive the changing economy, the US needs to start thinking global collaboration.
Eli de los Pinos, CEO of Aura Biosciences, had a hard time getting government-driven grants for her global company. She has the best European technology combined with European and American investors, making her company neither European nor American, cutting her off from government grant funding.
The new competitive business model is going to be global, so governments need to evaluate companies on potential rather than by their nationality.
As America loses economic dominance, it will also lose market share. According to Xiaolin Zhang, Head of R&D China for Astra Zeneca, China will be the largest pharmaceutical market in 2015, but R&D doesn’t reflect the country’s disease profile. In the West the biggest cancers are lung, breast, colorectal and prostate. In the East, liver, esophageal and gastric cancers follow lung as the top four killers, yet up until two years ago there was no drug to specifically target liver cancer. Personalized medicine is the future, which means targeted drug therapies.
The US needs to look to the future and develop global R&D practices in the life sciences, or risk missing market opportunities and fall behind.
Eli de los Pinos, CEO of Aura Biosciences, had a hard time getting government-driven grants for her global company. She has the best European technology combined with European and American investors, making her company neither European nor American, cutting her off from government grant funding.
The new competitive business model is going to be global, so governments need to evaluate companies on potential rather than by their nationality.
As America loses economic dominance, it will also lose market share. According to Xiaolin Zhang, Head of R&D China for Astra Zeneca, China will be the largest pharmaceutical market in 2015, but R&D doesn’t reflect the country’s disease profile. In the West the biggest cancers are lung, breast, colorectal and prostate. In the East, liver, esophageal and gastric cancers follow lung as the top four killers, yet up until two years ago there was no drug to specifically target liver cancer. Personalized medicine is the future, which means targeted drug therapies.
The US needs to look to the future and develop global R&D practices in the life sciences, or risk missing market opportunities and fall behind.
Comments
Post a Comment